BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 9c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($0.96), $0.09 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $1.75 million versus the consensus estimate of $4.55 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• Barclays sees global expansion intact, warns against market complacency
• Rank One Computing (ROC) Reiterated at Buy by Benchmark
• Darden Restaurants posts fiscal 2026 results, raises dividend, OKs buyback